2 days Ago By ABMN Staff
StockNews.com started coverage on shares of BIOLASE ( NASDAQ:BIOL – Free Report ) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the medical technology company’s stock.
BIOL has been the topic of several other reports. Benchmark reissued a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a report on Wednesday, October 2nd.
Ascendiant Capital Markets decreased their target price on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.
Check Out Our Latest Research Report on BIOL BIOLASE Stock Performance Institutional Inflows and Outflows A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC boosted its stake in BIOLASE, Inc. ( NASDAQ:BIOL – Free Report ) by 1,068.
0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.
43% of BIOLASE worth $27,000 at the end of the most recent quarter. 8.79% of the stock is currently owned by institutional investors and hedge funds.
About BIOLASE ( Get Free Report ) BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. Recommended Stories Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.
com's FREE daily email newsletter ..
